# Emergent BioSolutions awarded $704M BARDA contract for Ebola treatment

Emergent BioSolutions Inc. was awarded a 10-year contract by BARDA valued at up to $704 million for advanced development, manufacturing scale-up, and procurement of Ebanga treatment for Ebola virus disease.

- Type: Contract
- Announced: 2023-07-31
- Where: United States
- Value: $704.0M
- Status: announced
- Products: Ebanga (ansuvimab-zykl) treatment for Ebola
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Emergent BioSolutions](https://endata.com/companies/34613.md)
- [Biomedical Advanced Research and Development Authority](https://endata.com/companies/8807.md) (customer)

## Sources

- [investors.emergentbiosolutions.com](https://investors.emergentbiosolutions.com/news/news-details/2023/Emergent-BioSolutions-Awarded-10-Year-BARDA-Contract-Valued-at-up-to-a-Maximum-of-704-Million-for-Advanced-Development-and-Procurement-of-Ebanga-Treatment-for-Ebola-07-31-2023/default.aspx), 2023-07-31: "Emergent BioSolutions Inc. announced today that it was awarded a 10-year contract by the Biomedical Advanced Research and Development Authority (BARDA) ... valued at up to a maximum of $704 million."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.